Starling Oncology, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 6, 2026, reporting total operating revenue of $169.8 million for the third quarter and a net loss of $15.7 million.
Key Highlights
- Total operating revenue: $169,767 thousand for the three months ended September 30, 2026, up from $136,564 thousand in the same period of 2025, according to the filing.
- Specialty Pharmacy revenue: $109,304 thousand for Q3 2026, compared with $75,895 thousand in Q3 2025, as reported in the condensed consolidated statements of operations.
- Net loss: $15,748 thousand for Q3 2026, versus a net loss of $16,504 thousand in Q3 2025, the company disclosed.
- Nine-month net loss: $28,029 thousand for the nine months ended September 30, 2026, compared with $53,098 thousand for the same period of 2025.
- Total assets: $187,773 thousand as of September 30, 2026, up from $164,656 thousand at December 31, 2025.
- Accumulated deficit: $299,448 thousand as of September 30, 2026, versus $271,419 thousand at December 31, 2025.
- Shares outstanding: 101,991,024 shares of common stock as of November 3, 2026, per the filing cover page.
Starling Oncology Reports Q3 2026 Financial Results Under New Name
Starling Oncology, Inc. - formerly known as The Oncology Institute, Inc. - filed its quarterly report for the period ended September 30, 2026 on NASDAQ:STLN. The filing noted the company changed its name and address to 18000 Studebaker Road, Suite 800, Cerritos, California 90703. The company is classified as an accelerated filer and a smaller reporting company, according to the filing's cover page.
Total operating revenue for the nine months ended September 30, 2026 reached $478,490 thousand, compared with $360,772 thousand for the same period in 2025, the company disclosed. Revenue is split across three segments: patient services ($177,927 thousand nine-month), Specialty Pharmacy ($295,453 thousand nine-month), and clinical trials and other ($5,110 thousand nine-month). Operating expenses for the nine months totaled $492,601 thousand, resulting in a loss from operations of $14,111 thousand, compared with a loss from operations of $29,176 thousand in the same period of 2025.
The company reported a loss on debt extinguishment of $11,561 thousand in Q3 2026, with no comparable charge in Q3 2025, contributing to total other non-operating expense of $12,766 thousand for the quarter. Total stockholders' deficit widened to $37,355 thousand as of September 30, 2026 from $15,720 thousand at December 31, 2025. Long-term debt, net of unamortized debt issuance costs, stood at $72,520 thousand at quarter end, down from $77,400 thousand at year-end 2025. The filing also noted that VIE-related total assets usable only to settle VIE obligations were $116,080 thousand as of September 30, 2026, and VIE liabilities for which creditors have no recourse to the company's general credit totaled $102,663 thousand.
What Was Disclosed
Starling Oncology, Inc. disclosed its unaudited condensed consolidated financial results for Q3 and the nine months ended September 30, 2026, covering revenue by segment, operating losses, debt extinguishment charges, balance sheet changes, and variable interest entity details.



Please wait processing your request...